图文详情
Emerfetamab (AMG 673) is a dual-specificity T-cell engager (bispecific T-cell engager) with an extended half-life that targets both CD33 and CD3. By redirecting T cells towards CD33+ cells, Emerfetamab induces T-cell mediated cytotoxicity against progenitor cells in acute myeloid leukemia (AML).